Abstract
The prevalence of lung diseases is increasing year by year and existing drug therapies only provide symptomatic relief rather than targeting the actual cause. Nucleic acids can be used as an alternative therapeutic approach owing to their potential to reform a homeostatic balance by upregulating protective genes or downregulating damaging genes. However, their inherent properties, such as poor stability, ineffective cellular uptake, negative charge and so on, hinder their clinical utility. Such limitations can be overcome by exploiting the functional chemistry of polymeric micelles (PMs) for site-specific delivery, transfection efficiency and improved stability. With this objective, the present work describes the advancements made in designing nucleic acid-based PMs for treating lung diseases followed by approaches requiring consideration for clinical applications.
| Original language | English |
|---|---|
| Pages (from-to) | 1951-1960 |
| Number of pages | 10 |
| Journal | Nanomedicine |
| Volume | 17 |
| Issue number | 25 |
| DOIs | |
| State | Published - 1 Oct 2022 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- functionalization
- nucleic acids
- polymeric micelles
- pulmonary delivery
Fingerprint
Dive into the research topics of 'Role of nucleic acid-based polymeric micelles in treating lung diseases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver